Tags : first patient


Celyad Announces Successful Dosing of CYAD-01 IV in P-I THINK

Shots: The P-I THINK ongoing trial is assessing CYAD-01 in mCRC patients administering cyclophosphamide (300 mg/m²) and fludarabine (30 mg/m²), evaluating its safety and ATR CYAD-01 investigational CAR-T therapy with expressing NKG2D receptor of NK cells, administration has shown no toxicity till date in its first enrolled patient in THINK trial   CYAD-01 is under clinical […]Read More